Ziftomenib
Acute Myeloid Leukemia With 11q23 Abnormalities
Explore 25 assets in Acute Myeloid Leukemia With 11q23 Abnormalities →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06440135CT.gov Ziftomenib Maintenance Post Allo-HCT | — | Recruiting | — | — | — |
NCT04067336CT.gov First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With 11q23 Abnormalities
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ziftomenib (this asset) | Massachusetts General Hospital | P1/2 | CCC · 54 |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P2 | BBB |
| Cytarabine | Alice Mims | P3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
| Fludarabine | M.D. Anderson Cancer Center | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BBB |
| Nivestim | M.D. Anderson Cancer Center | P3 | BBB |
+42 more in the Acute Myeloid Leukemia With 11q23 Abnormalities cohort
Other indications for Ziftomenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P3 | B · 63 |
| Cancer | — | P1/2 | CCC · 48 |
| Mixed Phenotype Acute Leukemia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ziftomenib in Acute Myeloid Leukemia With 11q23 Abnormalities. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ziftomenib-acute-myeloid-leukemia-with-11q23-abnormalities
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →